Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,631
  • Shares Outstanding, K 33,441
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,260 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta -0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 796.02% ( +390.63%)
  • Historical Volatility 129.52%
  • IV Percentile 98%
  • IV Rank 83.91%
  • IV High 944.78% on 10/03/24
  • IV Low 20.50% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 109
  • Volume Avg (30-Day) 425
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 15,918
  • Open Int (30-Day) 12,542

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.26
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8820 +42.29%
on 11/11/24
1.4900 -15.77%
on 10/23/24
-0.2450 (-16.33%)
since 10/21/24
3-Month
0.8500 +47.65%
on 08/23/24
1.5699 -20.06%
on 09/09/24
+0.4074 (+48.07%)
since 08/21/24
52-Week
0.6000 +109.17%
on 08/16/24
5.6700 -77.87%
on 01/04/24
-3.2050 (-71.86%)
since 11/21/23

Most Recent Stories

More News
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024

Reviva Pharmaceuticals reports 108 patients completed a trial for schizophrenia treatment, with topline data expected December 2024.Quiver AI SummaryReviva Pharmaceuticals Holdings, Inc. announced that...

RVPH : 1.2625 (+3.91%)
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

RVPH : 1.2625 (+3.91%)
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

ALDX : 4.93 (+3.57%)
STIM : 0.8225 (+2.49%)
PGY : 9.24 (+5.36%)
QSI : 1.2850 (-7.55%)
MNOV : 2.0400 (+4.62%)
AXSM : 97.32 (+2.88%)
VSAT : 8.68 (+25.25%)
ZS : 208.62 (+3.82%)
BTM : 1.9500 (-1.52%)
RVPH : 1.2625 (+3.91%)
SPY : 594.30 (+0.64%)
XBI : 94.82 (+0.86%)
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

RVPH : 1.2625 (+3.91%)
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

RVPH : 1.2625 (+3.91%)
Reviva to Participate in the UBS Global Healthcare Conference

RVPH : 1.2625 (+3.91%)
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

RVPH : 1.2625 (+3.91%)
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at...

RVPH : 1.2625 (+3.91%)
Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 1.2625 (+3.91%)
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 1.2625 (+3.91%)

Business Summary

Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment...

See More

Key Turning Points

3rd Resistance Point 1.3900
2nd Resistance Point 1.3450
1st Resistance Point 1.2800
Last Price 1.2625
1st Support Level 1.1700
2nd Support Level 1.1250
3rd Support Level 1.0600

See More

52-Week High 5.6700
Fibonacci 61.8% 3.7333
Fibonacci 50% 3.1350
Fibonacci 38.2% 2.5367
Last Price 1.2625
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar